Kingworld Medicines Group Limited (1110.HK)
HKD 0.45
(1.12%)
HKD 0.45
(1.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 112.98 Million CNY | -2.78% |
| 2022 | 118.06 Million CNY | 0.55% |
| 2021 | 116 Million CNY | -7.74% |
| 2020 | 120.58 Million CNY | 5.38% |
| 2019 | 121.61 Million CNY | -0.04% |
| 2018 | 116.18 Million CNY | -10.63% |
| 2017 | 135.31 Million CNY | 7.39% |
| 2016 | 125.5 Million CNY | 30.22% |
| 2015 | 74.25 Million CNY | 66.17% |
| 2014 | 51.25 Million CNY | -15.87% |
| 2013 | 30.46 Million CNY | 1.4% |
| 2012 | 65.26 Million CNY | -15.94% |
| 2011 | 79.93 Million CNY | 18.3% |
| 2010 | 67.5 Million CNY | 17.75% |
| 2009 | 57.32 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 30.85 Million CNY | 155.11% |
| 2024 Q2 | 30.85 Million CNY | 0.0% |
| 2023 FY | - CNY | -2.78% |
| 2023 Q4 | 12.09 Million CNY | 0.0% |
| 2023 Q1 | 32.16 Million CNY | 12.95% |
| 2023 Q3 | 12.09 Million CNY | -62.4% |
| 2023 Q2 | 32.16 Million CNY | 0.0% |
| 2022 Q1 | 25.21 Million CNY | 26.42% |
| 2022 Q3 | 28.47 Million CNY | 12.93% |
| 2022 Q4 | 28.47 Million CNY | 0.0% |
| 2022 FY | - CNY | 0.55% |
| 2022 Q2 | 25.21 Million CNY | 0.0% |
| 2021 FY | - CNY | -7.74% |
| 2021 Q1 | 28.28 Million CNY | 173.19% |
| 2021 Q4 | 19.94 Million CNY | 0.0% |
| 2021 Q3 | 19.94 Million CNY | -29.48% |
| 2021 Q2 | 28.28 Million CNY | 0.0% |
| 2020 Q4 | 10.35 Million CNY | 0.0% |
| 2020 FY | - CNY | 5.38% |
| 2020 Q3 | 10.35 Million CNY | -70.2% |
| 2020 Q2 | 34.74 Million CNY | 0.0% |
| 2020 Q1 | 34.74 Million CNY | 157.63% |
| 2019 Q4 | 13.48 Million CNY | 0.0% |
| 2019 FY | - CNY | -0.04% |
| 2019 Q1 | 33.63 Million CNY | 101.18% |
| 2019 Q3 | 13.48 Million CNY | -59.9% |
| 2019 Q2 | 33.63 Million CNY | 0.0% |
| 2018 FY | - CNY | -10.63% |
| 2018 Q3 | 16.71 Million CNY | -41.2% |
| 2018 Q2 | 28.42 Million CNY | 0.0% |
| 2018 Q1 | 28.42 Million CNY | 101.07% |
| 2018 Q4 | 16.71 Million CNY | 0.0% |
| 2017 FY | - CNY | 7.39% |
| 2017 Q4 | 14.13 Million CNY | 0.0% |
| 2017 Q3 | 14.13 Million CNY | -51.91% |
| 2017 Q2 | 29.4 Million CNY | 0.0% |
| 2017 Q1 | 29.4 Million CNY | -20.52% |
| 2016 Q4 | 36.98 Million CNY | 0.0% |
| 2016 Q2 | 25.76 Million CNY | 0.0% |
| 2016 Q3 | 36.98 Million CNY | 43.56% |
| 2016 Q1 | 25.76 Million CNY | 61.36% |
| 2016 FY | - CNY | 30.22% |
| 2015 Q2 | 21.16 Million CNY | 0.0% |
| 2015 Q3 | 15.96 Million CNY | -24.55% |
| 2015 Q4 | 15.96 Million CNY | 0.0% |
| 2015 FY | - CNY | 66.17% |
| 2015 Q1 | 21.16 Million CNY | 89.23% |
| 2014 FY | - CNY | -15.87% |
| 2014 Q1 | 14.44 Million CNY | 102.51% |
| 2014 Q4 | 11.18 Million CNY | 0.0% |
| 2014 Q2 | 14.44 Million CNY | 0.0% |
| 2014 Q3 | 11.18 Million CNY | -22.58% |
| 2013 Q1 | 8.1 Million CNY | -44.41% |
| 2013 Q3 | 7.13 Million CNY | -11.95% |
| 2013 Q4 | 7.13 Million CNY | 0.0% |
| 2013 FY | - CNY | 1.4% |
| 2013 Q2 | 8.1 Million CNY | 0.0% |
| 2012 FY | - CNY | -15.94% |
| 2012 Q1 | 16.86 Million CNY | 0.0% |
| 2012 Q2 | 16.86 Million CNY | 0.0% |
| 2012 Q4 | 14.57 Million CNY | 0.0% |
| 2012 Q3 | 14.57 Million CNY | -13.61% |
| 2011 Q4 | 16.86 Million CNY | -15.8% |
| 2011 Q2 | 20.03 Million CNY | 0.0% |
| 2011 Q1 | 20.03 Million CNY | 0.0% |
| 2011 FY | - CNY | 18.3% |
| 2011 Q3 | 20.03 Million CNY | 0.0% |
| 2010 Q1 | 16.87 Million CNY | 0.0% |
| 2010 Q4 | 20.03 Million CNY | 18.7% |
| 2010 Q3 | 16.87 Million CNY | 0.0% |
| 2010 Q2 | 16.87 Million CNY | 0.0% |
| 2010 FY | - CNY | 17.75% |
| 2009 FY | - CNY | 0.0% |
| 2009 Q2 | 14.33 Million CNY | 0.0% |
| 2009 Q3 | 14.33 Million CNY | 0.0% |
| 2009 Q4 | 16.87 Million CNY | 17.75% |
| 2009 Q1 | 14.33 Million CNY | 0.0% |
| 2008 Q4 | 14.33 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| China Healthwise Holdings Limited | -117.45 Million HKD | 196.197% |
| Tycoon Group Holdings Limited | 147.38 Million HKD | 23.341% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | 779.54 Million HKD | 85.506% |